Answers are grounded in this paper and cite their sources.
Demonstrates cartilage preservation in osteoarthritis rats using a dual-action biomaterial, indicating innovative treatment potential.
High Resolution Image Download MS PowerPoint Slide Osteoarthritis (OA) treatment via intra-articular (IA) hyaluronic acid is hindered by rapid degradation and poor chondroprotection. To address these limitations, this study engineered a dual-action IA biomaterial by cross-linking Bletilla striata polysaccharide (BSP) with poly(ethylene glycol) diglycidyl ether (PEGDE). The resulting copolymer (BSPP) exhibited a 15% molecular weight increase and enhanced aqueous stability, showing only 5% degradation on day 3 compared to the complete dissolution of pristine BSP. In vitro, BSPP exhibited excellent biocompatibility, enhancing chondrocyte viability to 124.02 ± 2.14%, and protected cells against lipopolysaccharide-induced stress. In vivo, in a monosodium iodoacetate-induced OA rat model, BSPP significantly alleviated pain, maintaining a mechanical pain threshold of 48.24 ± 1.93 g at week 3 compared to 21.03 ± 1.67 g in the untreated group. Histological analysis at week 4 confirmed cartilage preservation, reducing the OARSI histopathology score from 9.714 ± 3.74 to 2.10 ± 1.52.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: